ArticleBMC infectious diseases2026
Antibacterial activity of imipenem-encapsulated chitosan/HPMCP nanoparticles against clinical Acinetobacter baumannii isolates.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant Acinetobacter baumannii is an important healthcare-associated pathogen, necessitating therapeutic strategies. This study evaluates the antibacterial efficacy of imipenem-encapsulated chitosan/hydroxypropyl methylcellulose phthalate (Imp-Chi) nanoparticles against clinical A. baumannii isolates.
methodsA. baumannii clinical isolates (n = 105) from hospitalized patients were characterized for antibiotic resistance via broth microdilution and classified as MDR, XDR, or PDR. An exploratory PCR screen was performed for the selected AmpC-family genes mox, cit, and dha. Imp-Chi nanoparticles were synthesized via ionic gelation, characterized for size, zeta potential, morphology, encapsulation efficiency, and drug release. Antibacterial activity was assessed via MIC assays against the A. baumannii clinical isolates. Recoverable bacterial burden in extracellular, cell-associated, and intracellular fractions of A549 and NCI-H292 infection models was quantified, alongside reactive oxygen species (ROS) and cytotoxicity assessments using MTT and LDH assays.
resultsIsolates exhibited high resistance to β-lactams (97.1-99.0%), carbapenems (94.3-98.1%), and aminoglycosides (92.4-96.2%), with 77.1% classified as PDR. No significant association was observed between the selected AmpC-family genes and resistance phenotypes (p > 0.05). Imp-Chi nanoparticles (291.3 nm, + 34.9 mV; spherical morphology with smooth surfaces) demonstrated optimal encapsulation efficiency (1.5 µg imipenem) and sustained drug release (70% over 10 h). MICs of Imp-Chi nanoparticles were significantly lower than free imipenem (p < 0.0001; ~0.31-fold reduction); while fractional inhibitory concentration index values clustered around 1.0, supporting an additive or near-additive rather than synergistic interaction, and the nanoparticles also reduced recoverable bacterial CFU across extracellular and host-cell-associated fractions in lung epithelial infection models in vitro. ROS levels in A. baumannii-infected cells decreased to near-baseline levels following Imp-Chi treatment (p < 0.0001). MTT and LDH readouts suggested limited cytotoxicity-associated effects at 100-200 µg/mL and concentration-dependent effects at higher concentrations, with apparent MTT-derived IC₅₀ values of approximately 740 µg/mL; however, nanoparticle-related assay interference and carrier-specific effects were not independently excluded.
conclusionsImp-Chi nanoparticles reduced imipenem MICs through additive or near-additive antibacterial contributions and may also provide formulation-related delivery advantages, while reducing bacterial burden in lung epithelial infection models and being associated with lower infection-associated ROS levels in vitro. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42919155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.